<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Propofol</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00818</strong>&#160; (APRD01201, DB05893, EXPT02558)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associated with less frequent side effects (e.g. drowsiness, nausea, vomiting) than with thiopental, methohexital, and etomidate. Propofol may be used prior to diagnostic procedures requiring anaesthesia, in the management of refractory status epilepticus, and for induction and/or maintenance of anaesthesia prior to and during surgeries.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00818/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00818/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00818.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00818.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00818.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00818.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00818.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00818">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Disoprofol</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IS</td></tr><tr><td>Propofol</td><td>German</td><td>INN</td></tr><tr><td>Propofol</td><td>Spanish</td><td>INN</td></tr><tr><td>Propofol</td><td>French</td><td>INN</td></tr><tr><td>Propofolum</td><td>Latin </td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Anepol</td><td>Ha Na Pharm</td></tr><tr><td>Anespro</td><td>Behrens</td></tr><tr><td>Anesvan</td><td>Chi Sheng</td></tr><tr><td>Critifol</td><td>Abbott</td></tr><tr><td>Diprivan</td><td>AstraZeneca</td></tr><tr><td>Disoprivan</td><td>AstraZeneca</td></tr><tr><td>Dormofol</td><td>Actavis</td></tr><tr><td>Fresofol</td><td>Boryung</td></tr><tr><td>Gobbifol</td><td>Gobbi</td></tr><tr><td>Hipnolam</td><td>AC Farma</td></tr><tr><td>Hypro</td><td>Celon</td></tr><tr><td>IV-Pro</td><td>Claris Lifesciences</td></tr><tr><td>Lipuro</td><td>B. Braun Medical</td></tr><tr><td>Oleo-Lax</td><td>Fada</td></tr><tr><td>Plofed</td><td>Warsaw Pharmaceutical Works</td></tr><tr><td>Profol</td><td>Biogalenic</td></tr><tr><td>Profolen</td><td>Blausiegel</td></tr><tr><td>Propofabb</td><td>Hospira</td></tr><tr><td>Propofil</td><td>Alvia</td></tr><tr><td>Propogen</td><td>Genepharm</td></tr><tr><td>Propolipid</td><td>Fresenius</td></tr><tr><td>Propovan</td><td>Bharat Serums</td></tr><tr><td>Propoven</td><td>Fresenius</td></tr><tr><td>Provive</td><td>AFT</td></tr><tr><td>Recofol</td><td>Bayer</td></tr><tr><td>Safol</td><td>Novell</td></tr><tr><td>Trivam</td><td>Hana Pharm</td></tr><tr><td>Troypofol</td><td>Troikaa</td></tr><tr><td>Unifol</td><td>Claris Lifesciences</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/hypnotics-and-sedatives">Hypnotics and Sedatives</a></li>
<li><a href="/mesh/anesthetics-intravenous">Anesthetics, Intravenous</a></li></ul></td></tr><tr><th>CAS number</th><td>2078-54-8</td></tr><tr><th>Weight</th><td>Average: 178.2707<br>Monoisotopic: 178.135765198</td></tr><tr><th>Chemical Formula</th><td>C<sub>12</sub>H<sub>18</sub>O</td></tr><tr><th>InChI Key</th><td>OLBCVFGFOZPWHH-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2,6-bis(propan-2-yl)phenol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CC(C)C1=CC=CC(C(C)C)=C1O</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00818.gif?1265922772">show</a>(7.9 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Cumenes</td></tr><tr><th>Direct parent</th><td>Cumenes</td></tr><tr><th>Alternative parents</th><td>Phenols and Derivatives; Polyamines; Enols</td></tr><tr><th>Substituents</th><td>phenol derivative; polyamine; enol</td></tr><tr><th>Classification description</th><td>This compound belongs to the cumenes. These are aromatic compounds containing a prop-2-ylbenzene moiety.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used for induction and/or maintenance of anaesthesia and for management of refractory status epilepticus. </td></tr><tr><th>Pharmacodynamics</th><td>Propofol is a sedative-hypnotic agent for use in the induction and maintenance of anesthesia or sedation. Intravenous injection of a therapeutic dose of propofol produces hypnosis rapidly with minimal excitation, usually within 40 seconds from the start of an injection (the time for one arm-brain circulation).</td></tr><tr><th>Mechanism of action</th><td>The action of propofol involves a positive modulation of the inhibitory function of the neurotransmitter gama-aminobutyric acid (GABA) through GABA-A receptors.</td></tr><tr><th>Absorption</th><td>Rapid - time to onset of unconsciousness is 15-30 seconds, due to rapid distribution from plasma to the CNS. Distribution is so rapid that peak plasma concentrations cannot be readily measured. Duration of action is 5-10 minutes. </td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>60 L/kg [healthy adults]</li>
</ul></td></tr><tr><th>Protein binding</th><td>95 to 99%, primarily to serum albumin and hemoglobin</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatically metabolized mainly by glucuronidation at the C1-hydroxyl. Hydroxylation of the benzene ring to 4-hydroxypropofol may also occur via CYP2B6 and 2C9 with subsequent conjugation to sulfuric and/or glucuronic acid. Hydroxypropofol has approximately 1/3 of hypnotic activity of propofol. </p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Propofol</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003549" target="_blank">Cytochrome P450 2B6</a></li></ul></td><td><a href="/metabolites/DBMET00193">4-Hydroxypropofol</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/194">Details</a></td></tr><tr><td>Propofol</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003682" target="_blank">UDP-glucuronosyltransferase 1-8</a></li>
<li><a href="/biodb/bio_entities/BE0003538" target="_blank">UDP-glucuronosyltransferase 1-9</a></li></ul></td><td><a href="/metabolites/DBMET00194">Propofol glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/195">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00194">Propofol glucuronide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01311">1-Quinol glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1484">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00193">4-Hydroxypropofol</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003682" target="_blank">UDP-glucuronosyltransferase 1-8</a></li>
<li><a href="/biodb/bio_entities/BE0003538" target="_blank">UDP-glucuronosyltransferase 1-9</a></li></ul></td><td><a href="/metabolites/DBMET01311">1-Quinol glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1485">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00193">4-Hydroxypropofol</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01312">4-Quinol sulfate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1486">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>It is chiefly eliminated by hepatic conjugation to inactive metabolites which are excreted by the kidney.</td></tr><tr><th>Half life</th><td>Initial distribution phase t<sub>1/2&#945;</sub>=1.8-9.5 minutes. Second redistirubtion phase t<sub>1/2&#946;</sub>=21-70 minutes. Terminal elimination phase t<sub>1/2&#947;</sub>=1.5-31 hours. </td></tr><tr><th>Clearance</th><td><ul>
	<li>23 &#8211; 50 mL/kg/min</li>
	<li>1.6 &#8211; 3.4 L/min [70 Kg adults]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Overdosage may increase pharmacologic and adverse effects or cause death. 
<p>IV LD<sub>50</sub>=53 mg/kg (mice), 42 mg/kg (rats). Oral LD<sub>50</sub> (as a solution in soybean oil)=1230 mg/kg (mice), 600 mg/kg (rats)</p></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9955</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9381</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.9153</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.722</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9343</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9883</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9036</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7352</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.7838</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5667</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9107</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.907</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9368</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9026</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9196</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.7429</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9282
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7195
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.7808
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.2996 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8987
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.9087
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>App pharmaceuticals llc</li>
<li>Bedford laboratories div ben venue laboratories inc</li>
<li>Hospira inc</li>
<li>Teva parenteral medicines inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.apppharma.com">APP Pharmaceuticals</a></li>
<li><a href="http://www.astrazeneca.ca">AstraZeneca Inc.</a></li>
<li><a href="http://www.baxter.com">Baxter International Inc.</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li><a href="http://www.hospira.com">Hospira Inc.</a></li>
<li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li>Sicor Pharmaceuticals</li>
<li><a href="http://www.tevapharm.com">Teva Pharmaceutical Industries Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Emulsion</td><td>Intravenous</td><td>10 mg/ml</td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Diprivan 10 mg/ml vial</td><td>0.93USD</td><td>ml</td></tr><tr><td>Propoven 1000 mg/100 ml vial</td><td>0.19USD</td><td>ml</td></tr><tr><td>Propoven 200 mg/20 ml ampul</td><td>0.19USD</td><td>ml</td></tr><tr><td>Propoven 500 mg/50 ml vial</td><td>0.19USD</td><td>ml</td></tr><tr><td>Propofol 10 mg/ml vial</td><td>0.13USD</td><td>ml</td></tr><tr><td>Propofol 1% emulsion vial</td><td>0.1USD</td><td>ml</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>5714520</td><td>1995-09-22</td><td>2015-09-22</td></tr><tr><td>Canada</td><td>2212794</td><td>2000-09-12</td><td>2015-03-17</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>liquid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>18 &#176;C</td><td>PhysProp</td></tr><tr><td>boiling point</td><td>256 &#176;C</td><td>PhysProp</td></tr><tr><td>water solubility</td><td>124 mg/L</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>logP</td><td>3.79</td><td>HANSCH,C ET AL. (1995)</td></tr><tr><td>pKa</td><td>11.1 (at 20 &#176;C)</td><td>SERJEANT,EP &amp; DEMPSEY,B (1979)</td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>1.58e-01 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>3.81</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>4.16</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-3</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>10.98</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>-5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>20.23</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>56.42</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>21.61</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>John R. Carpenter, &#8220;Propofol-based anesthetic and method of making same.&#8221; U.S. Patent US6150423, issued May, 1977.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=6150423&amp;tbm=pts" target="_blank">US6150423 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Vasile B, Rasulo F, Candiani A, Latronico N: The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med. 2003 Sep;29(9):1417-25. Epub 2003 Aug 6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12904852">Pubmed</a></li>
	<li>Ke JJ, Zhan J, Feng XB, Wu Y, Rao Y, Wang YL: A comparison of the effect of total intravenous anaesthesia with propofol and remifentanil and inhalational anaesthesia with isoflurane on the release of pro- and anti-inflammatory cytokines in patients undergoing open cholecystectomy. Anaesth Intensive Care. 2008 Jan;36(1):74-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18326136">Pubmed</a></li>
	<li>Hong JY, Kang YS, Kil HK: Anaesthesia for day case excisional breast biopsy: propofol-remifentanil compared with sevoflurane-nitrous oxide. Eur J Anaesthesiol. 2008 Feb 26;:1-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18298873">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D00549" target="_blank">D00549 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C07523" target="_blank">C07523 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=4943" target="_blank">4943 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46504991" target="_blank">46504991 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.4774.html" target="_blank">4774 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=8495" target="_blank">8495 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL526" target="_blank">CHEMBL526 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000662" target="_blank">DAP000662 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA451141" target="_blank">PA451141 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>HET</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/msd-srv/chempdb/cgi-bin/cgi.pl?FUNCTION=getByCode&amp;CODE=PFL" target="_blank">PFL <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2242973" target="_blank">2242973 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic2/propof.htm" target="_blank">http://www.rxlist.com/cgi/generic2/propof.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/propofol.html" target="_blank">http://www.drugs.com/propofol.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Propofol" target="_blank">Propofol <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>N01AX10<ul class="atc-drug-tree"><li><a href="/atc/N#N">N &#8212; NERVOUS SYSTEM</a></li><li><a href="/atc/N01#N01">N01 &#8212; ANESTHETICS</a></li><li><a href="/atc/N01A#N01A">N01A &#8212; ANESTHETICS, GENERAL</a></li><li><a href="/atc/N01AX#N01AX">N01AX &#8212; Other general anesthetics</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>28:04.92</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB00818.pdf?1265922797">show</a>(168 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB00818.pdf?1265922737">show</a>(71.9 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00382">Tacrine</a></td><td>The metabolism of Tacrine, a CYP1A2 substrate, may be reduced by Propofol, a CYP1A2 inhibitors. Monitor the efficacy and toxicity of Tacrine if Propofol is initiated, discontinued or if the dose is changed.</td></tr><tr><td><a href="/drugs/DB00697">Tizanidine</a></td><td>Propofol may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>